All In Biotech

Drug Trial Radar · NCT03919071

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Feb 20, 2020

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Sponsor type
NIH
First posted
Apr 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib after radiation therapy may work better than treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade glioma.

Conditions

  • Anaplastic Astrocytoma
  • Anaplastic Astrocytoma, Not Otherwise Specified
  • Anaplastic Ganglioglioma
  • Anaplastic Pleomorphic Xanthoastrocytoma
  • Glioblastoma
  • Malignant Glioma
  • WHO Grade 3 Glioma
  • WHO Grade 4 Glioma

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood

  • Dabrafenib MesylateDrug

    Given PO

  • Lumbar PunctureProcedure

    Undergo lumbar puncture

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Radiation TherapyRadiation

    Undergo RT

  • Trametinib Dimethyl SulfoxideDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS) for stratum 1Time frame: From the date of diagnosis until disease progression date, secondary malignant neoplasm occurrence date, death date of any cause, or last follow-up, assessed up to 5 years

Locations

131 sites in 2 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • Banner Children's at Desert

    Mesa, Arizona

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Kaiser Permanente Downey Medical Center

    Downey, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

  • Nicklaus Children's Hospital

    Miami, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Arnold Palmer Hospital for Children

    Orlando, Florida

  • Nemours Children's Hospital

    Orlando, Florida

  • Sacred Heart Hospital

    Pensacola, Florida

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida

  • Tampa General Hospital

    Tampa, Florida

  • Saint Joseph's Hospital/Children's Hospital-Tampa

    Tampa, Florida

  • Saint Mary's Medical Center

    West Palm Beach, Florida

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital

    Atlanta, Georgia

  • Memorial Health University Medical Center

    Savannah, Georgia

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho

  • Lurie Children's Hospital-Chicago

    Chicago, Illinois

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.